A Double-blind, Placebo-controlled, Randomized Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics After Single or Repeat Twice-daily Doses of AP02, a Nebulized Formulation of Nintedanib

nintedanib inhaled (AP02) - Avalyn Pharma

IMC001 - Immunofoco

https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A2088

Michelle Palacios, PhD; Melissa Rhodes, PhD; Rebecca Boone, B.S., M.A.; Howard M. Lazarus, MD, FCCP; Stephen Pham, PhD; Craig S. Conoscenti, MD, FCCP, ATSF

Mar 16, 2025